A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 22% of the time (1,598 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-09-14. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celltransplantradiationmarrowtumors
  Phrases that lowered it: malefirst dose28subjectsdrug
• Sponsor's past termination rate: 16.3% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 42 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Keywords listed: 14 (raises risk) · Design
• Drug's FAERS reports marked serious: 78.1% (lowers risk) · Drug's FDA history
• Minimum age: 1 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Sponsor's past trials: 141 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 6672 (lowers risk) · Drug's FDA history
• Maximum age: 21 (raises risk) · Who can join
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports before start: 20315 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports with a death: 21.6% (raises risk) · Drug's FDA history
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors NCT02415153 · started 2015 · scored riskier than 70% of active trials completed
• INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas NCT04295759 · started 2020 · scored riskier than 87% of active trials completed
• Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex NCT03180736 · started 2017 · scored riskier than 65% of active trials completed
• Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma NCT03731832 · started 2018 · scored riskier than 41% of active trials completed
• Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed/Refractory Advanced and/or Metastatic Solid Tumors NCT03510104 · started 2018 · scored riskier than 39% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.